skip to primary navigationskip to content
 

Tiny Cages that deliver medicines

Can we solve common issues of cancer treatments through the use of a nano-sized crystal?

Common cancer treatments today can be incredibly toxic: some are insoluble in water and therefore require higher doses, and some are non-specific – affecting more than just the unhealthy areas of the body. Treatments also tend to not last very long and require patients to undergo numerous injections every week.

Over the years, researchers have engineered potential solutions to these problems, aiming to create solutions with slow and controlled drug delivery. Slow release allows for fewer and less frequent injections, while controlled delivery assists with less toxic side effects. Various advanced materials (some that mimic nature) are used, including polymers, peptides, and viruses. In my group, we have utilised nano-sized cages (called metal-organic frameworks) to act as both a carrier and protector, and traffic therapeutic molecules into cells.

Metal-organic frameworks are made up of two components: an organic linker and a metal cluster. They can be built from a variety of different molecule combinations. Metals that we use are biologically compatible, such as zirconium.  The material chemistry is easily tuneable, and we can functionalise these materials to be targeted to specific cell receptors. This decreases off-targeting side effects and improves efficiency of treatment. We can also design the metal-organic framework to have large porosity, which is useful for encapsulating big biologic molecules compared with smaller synthetic drugs. These biologic macromolecules offer advantages over small drugs, especially related to specificity; therefore, designing a material to accommodate them offers much potential.

My research focuses on the design of these nano-sized cages to extend a drug’s efficacy – or potency – and encapsulation of a newer form of therapy (small interfering RNA) into the framework. This newer form of therapy is involved in a cellular mechanism called RNA interference, and has the ability to decrease the expression of a gene of interest. For cancer applications, this is incredibly useful and a very powerful technique. If one can limit the expression of a growth gene, for instance, it is much easier to remove a tumour before it gets too large and becomes malignant.

The potential for this research as a platform technology is wide ranging. We hope that in some years’ time, we can engineer a better solution for patients that is longer lasting, has less side effects, and involves zero reliance on patient compliance. 

Michelle Teplensky

NanoDTC Associate

RSS Feed Latest news

NanoDTC Associates Competition - Deadline 27th October

Oct 10, 2017

The NanoDTC Associates competition is and opportunity for Cambridge PhD students working in nano related areas to become affiliatedto the NanoDTC and also receive a travel grant of up to £3000. Applications accepted until Fri 27th Oct.

NanoDTC-Impulse-Maxwell Innovation Seminar Series - Prof. Ijeoma Uchegbu, Nanomerics

Oct 10, 2017

The first event in the joint NanoDTC-Impulse-Maxwell Innovation Seminar Series kicks off with a series of brilliant speakers who are at different stages in their Innovation  and Entrepreneurship journey.

Learning About Leadership in Antarctica

Aug 30, 2017

Hannah Laeverenz Schlogelhofer (c2014) writes about her experience being part of a leadership programme for creating change towards a more sustainable future

NanoDTC Translational Prize Fellow's nano-battery wins accolades

Jul 27, 2017

Jean de La Verpilliere (c2013), NanoDTC Translational Prize Fellow and Managing Director of the newly formed startup Echion Technologies has won prizes in the Royal Society of Chemistry 2017 Emerging Technologies Competition and the Kings' College Entrepreneurship Prize